Nature cardiovascular research · 2025
ANTXR1 blockade enhances cardiac function in preclinical models of heart failure.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Boccella Nicola, Yu GuoJun, Seaman Steven, Feng Yang, Lee Jaewon, Tomassoni-Ardori Francesco, Yang Liping, Hsu Kuo-Sheng, Dunleavey James M, Becker Jodi, Hilton Mary Beth, Morris Karen, Borchin Niza, So Daeho, Bajgain Pradip, Yanpallewar Sudhirkumar, Gross Ryan T, Dewan Krish C, Bowles Dawn E, Yuen Darren A, Tessarollo Lino, St Croix Brad
Аннотация
Heart disease, a leading cause of mortality worldwide, is in urgent need of improved therapies. Fibrosis, an accumulation of collagen-rich extracellular matrix in response to injury, is a hallmark of heart disease, but clinical agents that can interfere with the fibrotic pathway do not yet exist. Here we show that ANTXR1/TEM8, a pathology-induced transmembrane protein required for collagen removal, exacerbates injury in multiple models of heart failure. Genetic disruption of Antxr1 and treatment with human neutralizing antibodies prevented heart deterioration following acute myocardial infarction. ANTXR1 pharmacological blockade also improved heart function in models of pressure overload and obesity-induced heart disease with preserved ejection fraction. Improved heart function was accompanied by enhanced exercise tolerance. Mechanistic studies revealed an ANTXR1-antibody-driven improvement in post-infarct scar formation followed by attenuation of late-stage, chronic TGFβ-mediated extracellular matrix remodeling. Thus, ANTXR1-mediated collagen turnover during heart failure is both maladaptive and druggable, providing avenues for therapeutic intervention.